Warning: The NCBI web site requires JavaScript to function. more...
Interpreting interest in interferon-alpha.
Thibault DL, Utz PJ.
Arthritis Res Ther. 2003;5(5):246-8. Epub 2003 Aug 8. Review. No abstract available.
Related citations
[Interferon-alpha: a key cytokine in systemic lupus erythematosus pathogenesis].
Mathian A, Koutouzov S.
Rev Med Interne. 2008 Sep;29(9):696-700. Epub 2008 Jun 3. French.
The central role of dendritic cells and interferon-alpha in SLE.
Pascual V, Banchereau J, Palucka AK.
Curr Opin Rheumatol. 2003 Sep;15(5):548-56. Review.
Antimalarial agents: closing the gate on Toll-like receptors?
Lafyatis R, York M, Marshak-Rothstein A.
Arthritis Rheum. 2006 Oct;54(10):3068-70. No abstract available.
Type I IFN protects against murine lupus.
Hron JD, Peng SL.
J Immunol. 2004 Aug 1;173(3):2134-42.
Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy.
Schmidt KN, Ouyang W.
Lupus. 2004;13(5):348-52. Review.
Interferon-alpha-inducible proteins are novel autoantigens in murine lupus.
Hueber W, Zeng D, Strober S, Utz PJ.
Arthritis Rheum. 2004 Oct;50(10):3239-49.
How does interferon-α insult the vasculature? Let me count the ways.
Kaplan MJ, Salmon JE.
Arthritis Rheum. 2011 Feb;63(2):334-6. doi: 10.1002/art.30161. No abstract available.
[Pathophysiology of systemic lupus erythematosus].
Blanco P, Pellegrin JL, Moreau JF, Viallard JF.
Presse Med. 2007 May;36(5 Pt 2):825-34. Epub 2007 Jan 5. Review. French.
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.
Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL.
J Exp Med. 2005 Oct 17;202(8):1131-9.
Interferon-alpha: a new target for therapy in systemic lupus erythematosus?
Crow MK.
Arthritis Rheum. 2003 Sep;48(9):2396-401. Review. No abstract available.
Microarray analysis of gene expression in lupus.
Crow MK, Wohlgemuth J.
Arthritis Res Ther. 2003;5(6):279-87. Epub 2003 Oct 13. Review.
Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor.
Kono DH, Baccala R, Theofilopoulos AN.
Autoimmunity. 2003 Dec;36(8):503-10. Review.
Interferon pathway activation in systemic lupus erythematosus.
Curr Rheumatol Rep. 2005 Dec;7(6):463-8. Review.
The genetic basis of systemic lupus erythematosus--knowledge of today and thoughts for tomorrow.
Prokunina L, Alarcon-Riquelme M.
Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R143-8. Epub 2004 Feb 5. Review.
Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J.
Ann Rheum Dis. 2009 Sep;68(9):1440-6. Epub 2008 Sep 4.
C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis.
Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Rönnblom L, Sturfelt G, Eloranta ML, Bengtsson AA.
Arthritis Rheum. 2009 Oct;60(10):3081-90.
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK.
Arthritis Rheum. 2005 May;52(5):1491-503.
An essential role for IFN-alpha in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential.
Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobé P.
J Interferon Cytokine Res. 2004 Dec;24(12):717-28.
Systemic lupus erythematosus.
Mohty M.
N Engl J Med. 2008 May 29;358(22):2412-3; author reply 2413. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on